Tor Molden, Norway
Pfizer VaccinesAuthor Of 1 Presentation
PNEUMOCCOCAL DISEASE AMONG ELDERLY IN NORDIC COUNTRIES: DIFFERENT NEEDS FOR BROADER PROTECTION (ID 229)
Abstract
Background
The Nordic countries have different pediatric PCV programmes. In 2017, Norway and Denmark were using PCV13, Sweden both PCV10 and PCV13 and Finland used PCV10. All programmes have demonstrated high effectiveness in children, but with different indirect effect among elderly.
Methods
The IPD incidence for the year 2017 in +65 years of age was evaluated together with serotype specific coverage of licensed vaccines and developmental pneumococcal conjugate vaccines (PCVs) using data from the ECDC.
Results
Table: IPD incidence per 100 000 (%) by vaccine serotypes in +65 population, 2017
| Norway | Denmark | Sweden | Finland | |
| Pneumococcal Conjugate Vaccines: | ||||
| PCV10-types | 1,74 (4,8) | 1,9 (4,5) | 2,2 (5,1) | 3,9 (10,3) |
| PCV13-types | 8,6 (23,9) | 5,4 (12,8) | 12,5 (29,1) | 19,7 (51,9) |
| PCV15-types | 16,5 (45,8) | 10,7 (25,4) | 17,9 (41,7) | 23,1 (60,9) |
| PCV20-types | 22,2 (61,6) | 28,5 (67,7) | 24,9 (58,0) | 25,7 (67,7) |
| Pneumococcal Polysaccharide Vaccine: | ||||
| PPV23-types | 26,2 (72,9) | 34,26 (81,1) | 27,2 (63,4) | 26,1 (68,8) |
| Total IPD: | ||||
| All serotypes | 36,0 (100) | 42,2 (100) | 42,9 (100) | 38,0 (100) |
Conclusions
There are major differences in the serotype distribution in IPD among elderly between the Nordic countries associated with the choice of PCV in the pediatric programme. A substantial amount of IPD amongst elderly can be addressed by direct vaccination.